Business News, In Brief
Executive Summary
Some companies must answer to shareholders as blockbuster drugs come off patent, while others look to their pipeline’s future in diverse collaborations.
You may also be interested in...
Actelion's Macitentan Meets Primary Endpoint In Pivotal SERAPHIN Study, Approval Filings Expected In Fourth Quarter
Swiss biotech Actelion expects to submit its next-generation PAH therapy macitentan for approval in the fourth quarter of this year, giving it time to replace current top-selling product Tracleer before that product loses patent protection in 2015.
First the Activists, Now The Competition: Actelion Faces Continued Challenges
Actelion may have rebuffed activist shareholders Elliott Advisors, but it now faces growing competition in its core PAH franchise.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.